Skip to main content
Public beta This website is in public beta – please give your feedback.

Example clinical scenario

A 22-year-old male is referred to a metabolic bone clinic having presented to his GP complaining of lower limb pain. An initial biochemical evaluation reveals hypophosphataemia, with phosphate levels of 0.46mmol/l (normal range is between 0.8 and 1.2mmol/l), elevated alkaline phosphatase but normal serum calcium (2.25mmol/l) and parathyroid hormone levels. Examination in the clinic reveals short stature (a height of 160cm) with an atypical gait. Plain radiographs of the lower limbs demonstrate mild bowing, femoral pseudo-fractures and osteoarthritis in the hip and knee. Spot urinary calcium, phosphate and creatinine analyses indicate renal phosphate wasting.

When to consider genomic testing

Consider genomic testing for a patient presenting with hypophosphataemia with no identifiable cause, with evidence of decreased renal phosphate reabsorption, which has or could lead to a presentation with rickets.

For further information, see Hereditary hypophosphataemic rickets.

What do you need to do?

  • Consult the National Genomic Test Directory. From here you can access the rare and inherited disease eligibility criteria, which provides information about individual tests and their associated eligibility criteria. You can also access a spreadsheet of all available tests.
  • To find out which genes are included on different gene panels, see the NHS Genomic Medicine Service (GMS) Signed Off Panels resource.
  • For patients who meet the test directory’s eligibility criteria and do not have a personal or family history of a genetic variant in a hereditary hypophosphataemic gene, select the following:
    • R154 Hypophosphataemia or rickets. This panel currently comprises the following genes: ALPL, CYP27B1, CYP2R1, DMP1, ENNP1, FAM20C, FGF23, OCRL, PHEX, SLC34A1, SLC34A3 and VDR. It detects small variants and copy number variants (CNVs) by small gene panel sequencing.
  • Similar or overlapping tests include:
    • R104 Skeletal dysplasia. Patients with clinical features indicative of a likely monogenic skeletal dysplasia should be evaluated via this panel. It includes large gene panel sequencing (of over 400 genes), whole exome sequencing (WES) and whole genome sequencing (WGS).
  • For patients presenting with hereditary hypophosphataemia, where a genetic diagnosis in a relevant predisposition gene has been established in another family member, single gene testing for that specific variant should be considered. R240 Diagnostic testing for known mutation(s) could be selected if the pathogenic variant report about the close family member is available and testing was performed in an accredited laboratory.
  • For tests that are undertaken using WGS, you will need to:
  • For tests that do not include WGS, you should use your local Genomic Laboratory Hub test order and consent (record of discussion) forms.
  • These tests are DNA based, and an EDTA sample (purple-topped tube) is required. The sample is best stored at a temperature of four degrees Celsius until it can be posted to the genomic laboratory.
  • Information about patient eligibility and test indications was correct at the time of writing. When requesting a test, please refer to the National Genomic Test Directory to confirm the right test for your patient.

Resources

For clinicians

↑ Back to top
  • Last reviewed: 18/07/2023
  • Next review due: 18/07/2024
  • Authors: Dr Paul Newey
  • Reviewers: Dr Louise Izatt, Professor Márta Korbonits